 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Fondaparinux or Enoxaparin for Deep Venous Thrombosis?
1 June 2004 | Volume 140 Issue 11 | Page I-44
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis. A Randomized Trial." It is in the 1 June 2004 issue of Annals of Internal Medicine (volume 140, pages 867-873). The authors are H.R. Büller, B.L. Davidson, H. Decousus, A. Gallus, M. Gent, F. Piovella, M.H. Prins, G. Raskob, A.E.M. Segers, R. Cariou, O. Leeuwenkamp, and A.W.A. Lensing, for The Matisse Investigators.
What is the problem and what is known about it so far?
A blood clot inside the deep veins of the legs causes deep venous thrombosis (DVT). Pieces of the clot can break off, travel to the lungs, and cause serious and even fatal complications. Doctors usually give blood thinners to patients with DVT for several months to prevent pieces of clots from breaking loose and to stop new clots from forming. Vitamin K antagonists (warfarin, also known by the brand name Coumadin) are blood thinners that can be taken by mouth, but they take about a week to adequately thin blood and block clotting. Thus, patients with DVT must take other blood thinners during the first several days after a vitamin K antagonist is given. For many years, doctors initiated therapy for DVT with a blood-thinning drug known as unfractionated heparin. They gave this drug through a needle in a vein for a few days while patients started vitamin K antagonist therapy in the hospital. More recently, doctors have been using another preparation of heparin, low-molecular-weight heparin (LMWH), or drugs that selectively block clotting (factor Xa inhibitor). Both LMWH and factor Xa inhibitors can be injected under the skin, can be given at home, and do not require close monitoring of the dose. Several studies show that both drugs are safe and effective for treating DVT, but we do not know whether one is better than the other.
Why did the researchers do this particular study?
To see whether fondaparinux (factor Xa inhibitor) and enoxaparin (LMWH) have similar safety and efficacy for treating DVT.
Who was studied?
2205 adults with symptomatic DVT from 154 centers worldwide.
How was the study done?
The researchers randomly assigned 2205 patients with DVT to receive either fondaparinux once daily or enoxaparin twice daily. Both drugs were injected under the skin for at least 5 days. The patients and their doctors did not know who received which drug. All patients were also given blood thinner pills (vitamin K antagonists) for 3 months. During that time, doctors routinely checked for complications, such as bleeding, and also for evidence of new or repeated clots in the legs, lungs, or both.
What did the researchers find?
About 1% of the patients in each group had a major bleeding complication during the first week or so of treatment. About 4% in each group had repeated clots within 3 months. About 3% to 4% in each group died during follow-up. Most of the deaths were due to causes other than the clots or bleeding.
What were the limitations of the study?
Most patients received initial treatment in the hospital.
What are the implications of the study?
Fondaparinux and enoxaparin have similar safety and efficacy for initial treatment of patients with DVT.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. I. Weitz, J. Hirsh, and M. M. Samama New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 234S - 256S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 340S - 380S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Crowther and T. E. Warkentin Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents Blood, May 15, 2008; 111(10): 4871 - 4879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Groce Initial management of deep venous thrombosis in the outpatient setting Am. J. Health Syst. Pharm., May 1, 2008; 65(9): 866 - 874. [Full Text] [PDF]
|
|
|
|
 |
|
 A. G.G. Turpie Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C1 - C7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Laporte, P. Mismetti, H. Decousus, F. Uresandi, R. Otero, J. L. Lobo, M. Monreal, and the RIETE Investigators Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous Thromboembolism: Findings From the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry Circulation, April 1, 2008; 117(13): 1711 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. F. Tapson Acute Pulmonary Embolism N. Engl. J. Med., March 6, 2008; 358(10): 1037 - 1052. [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Gross and J. I. Weitz New Anticoagulants for Treatment of Venous Thromboembolism Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 380 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Spencer, J. M. Gore, D. Lessard, J. D. Douketis, C. Emery, and R. J. Goldberg Patient Outcomes After Deep Vein Thrombosis and Pulmonary Embolism: The Worcester Venous Thromboembolism Study Arch Intern Med, February 25, 2008; 168(4): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G.G. Turpie New oral anticoagulants in atrial fibrillation Eur. Heart J., January 2, 2008; 29(2): 155 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Spyropoulos Outpatient-Based Primary and Secondary Thromboprophylaxis With Low-Molecular-Weight Heparin Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 63 - 74. [Abstract] [PDF]
|
|
|
|
|
|
The van Gogh Investigators Idraparinux versus Standard Therapy for Venous Thromboembolic Disease N. Engl. J. Med., September 13, 2007; 357(11): 1094 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The van Gogh Investigators Extended Prophylaxis of Venous Thromboembolism with Idraparinux N. Engl. J. Med., September 13, 2007; 357(11): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, M. O'Donnell, and J. W. Eikelboom Beyond Unfractionated Heparin and Warfarin: Current and Future Advances Circulation, July 31, 2007; 116(5): 552 - 560. [Full Text] [PDF]
|
|
|
|
|
|
G. Agnelli, A. Gallus, S. Z. Goldhaber, S. Haas, M. V. Huisman, R. D. Hull, A. K. Kakkar, F. Misselwitz, S. Schellong, and for the ODIXa-DVT Study Investigators Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study Circulation, July 10, 2007; 116(2): 180 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Nutescu Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches Am. J. Health Syst. Pharm., June 1, 2007; 64(11_Supplement_7): S5 - S13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects J. Clin. Pharmacol., February 1, 2007; 47(2): 218 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Scarvelis and P. S. Wells Diagnosis and treatment of deep-vein thrombosis. Can. Med. Assoc. J., October 24, 2006; 175(9): 1087 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Levine, D. McCollum, and M. J. Hursting How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? Chest, September 1, 2006; 130(3): 681 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A Nutescu, A. K Wittkowsky, P. P Dobesh, D. W Hawkins, and W. E Dager Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach Ann. Pharmacother., September 1, 2006; 40(9): 1558 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kearon, J. S. Ginsberg, J. A. Julian, J. Douketis, S. Solymoss, P. Ockelford, S. Jackson, A. G. Turpie, B. MacKinnon, J. Hirsh, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA, August 23, 2006; 296(8): 935 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. de Moerloose, C. M. Samama, and S. Motte Management of venous thromboembolism: [Traitement de la maladie thromboembolique veineuse]. Can J Anesth, June 1, 2006; 53(6_suppl): S80 - S88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Fifth Organization to Assess Strategies in Acu Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes N. Engl. J. Med., April 6, 2006; 354(14): 1464 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Wiles and B J Hunt Anticoagulation via anti-Factor Xa inhibition Lupus, March 1, 2006; 15(3): 167 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 A. D Blann and G. Y H Lip Venous thromboembolism BMJ, January 28, 2006; 332(7535): 215 - 219. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Bauer New Anticoagulants Hematology, January 1, 2006; 2006(1): 450 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Prandoni How I treat venous thromboembolism in patients with cancer Blood, December 15, 2005; 106(13): 4027 - 4033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin, R. J. Cook, V. J. Marder, J.-A. I. Sheppard, J. C. Moore, B. I. Eriksson, A. Greinacher, and J. G. Kelton Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Blood, December 1, 2005; 106(12): 3791 - 3796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mismetti, S. Quenet, M. Levine, G. Merli, H. Decousus, E. Derobert, and S. Laporte Enoxaparin in the Treatment of Deep Vein Thrombosis With or Without Pulmonary Embolism: An Individual Patient Data Meta-analysis Chest, October 1, 2005; 128(4): 2203 - 2210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The PREPIC Study Group Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) Randomized Study Circulation, July 19, 2005; 112(3): 416 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E Dager, J. H King, J. M Branch, S. L Chow, R. E Ferrer, S. Pak, P. Y Togioka, and R. H White Tinzaparin in Outpatients with Pulmonary Embolism or Deep Vein Thrombosis Ann. Pharmacother., July 1, 2005; 39(7): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Haines and E. A. Nutescu Current and emerging treatment options for venous thrombosis: A case discussion Am. J. Health Syst. Pharm., March 15, 2005; 62(6): 593 - 605. [Full Text] [PDF]
|
|
|
|
|
|
J.-N. Fiessinger, M. V. Huisman, B. L. Davidson, H. Bounameaux, C. W. Francis, H. Eriksson, T. Lundstrom, S. D. Berkowitz, P. Nystrom, M. Thorsen, et al. Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis: A Randomized Trial JAMA, February 9, 2005; 293(6): 681 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB Evid. Based Med., November 1, 2004; 9(6): 163 - 163. [Full Text] [PDF]
|
|
|
|
 |
|
 23 Apr 2004 to 23 Jul 2004 Evid. Based Nurs., October 1, 2004; 7(4): e4 - e4. [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz, J. Hirsh, and M. M. Samama New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 265S - 286S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz New Anticoagulants for Treatment of Venous Thromboembolism Circulation, August 31, 2004; 110(9_suppl_1): I-19 - I-26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Fondaparinux vs. Enoxaparin for Acute Symptomatic DVT Journal Watch Cardiology, July 30, 2004; 2004(730): 2 - 2. [Full Text]
|
|
|
|
 |
|
 DVT Treatment Is Getting Simpler Journal Watch Emergency Medicine, June 30, 2004; 2004(630): 1 - 1. [Full Text]
|
|
|
|
 |
|
 P. Prandoni Toward the Simplification of Antithrombotic Treatment of Venous Thromboembolism Ann Intern Med, June 1, 2004; 140(11): 925 - 926. [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit Thrombophilia and New Anticoagulant Drugs Hematology, January 1, 2004; 2004(1): 424 - 438. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
